Amedisys Inc. (NASDAQ:AMED) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totalling 1,114,930 shares, a decrease of 60.2% from the September 15th total of 2,803,524 shares. Based on an average daily volume of 227,857 shares, the short-interest ratio is presently 4.9 days. Currently, 3.4% of the shares of the stock are short sold.
Shares of Amedisys (NASDAQ:AMED) opened at 46.12 on Wednesday. Amedisys has a 52 week low of $31.16 and a 52 week high of $55.16. The stock has a 50 day moving average price of $47.74 and a 200 day moving average price of $49.83. The firm has a market cap of $1.55 billion, a PE ratio of 40.35 and a beta of 0.96.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The company earned $360 million during the quarter, compared to analyst estimates of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. Equities analysts expect that Amedisys will post $1.69 earnings per share for the current year.
A number of equities analysts have issued reports on the company. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a report on Tuesday, July 5th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $51.75.
Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Amedisys by 2.8% in the first quarter. Prudential Financial Inc. now owns 75,959 shares of the company’s stock valued at $3,672,000 after buying an additional 2,100 shares during the period. M&T Bank Corp purchased a new stake in shares of Amedisys during the first quarter valued at about $367,000. BlackRock Inc. raised its stake in shares of Amedisys by 7.0% in the first quarter. BlackRock Inc. now owns 123,381 shares of the company’s stock valued at $5,964,000 after buying an additional 8,077 shares during the period. Finally, A.R.T. Advisors LLC raised its stake in shares of Amedisys by 77.5% in the first quarter. A.R.T. Advisors LLC now owns 50,626 shares of the company’s stock valued at $2,447,000 after buying an additional 22,100 shares during the period. 91.43% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.